Fuzheng Huayu Capsule Improves Survival in Patients with Hepatitis B-related Cirrhosis and Overt Hepatic Encephalopathy

Objective: Fuzheng Huayu (FZHY) capsules exert anti-liver fibrosis and cirrhosis effects. This study aimed to determine the effect of FZHY on the 6-month survival rate of patients with overt hepatic encephalopathy (OHE) and hepatitis B-related cirrhosis (HBC). Methods: A total of 517 patients with OHE and HBC treated between January 2008 and July 2018 were enrolled. Patients were divided into the FZHY (n = 129) and control groups (n = 388), and the 6-month survival rates were compared between the two groups. Propensity score matching (PSM) was used to reduce the bias caused by confounding factors. Results: In multivariable regression analysis, FZHY therapy was an independent protective factor of 6-month survival. After PSM (1:2), the FZHY and control group comprised 126 and 252 patients, respectively. The 6-month survival rate was remarkably higher in the FZHY group than in the control group (P < 0.005). FZHY users, especially those with a model for end-stage liver disease score ≥ 20 and Child-Pugh class C, benefited significantly from FZHY therapy. Conclusions: Adjuvant therapy with FZHY may be associated with improved survival in patients with OHE and HBC. However, further clinical studies are required to validate our findings.